Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging
1
조회
0
다운로드
17
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to compare the diagnostic performances of Liver Imaging Reporting and Data System (LI-RADS) 2018 and Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) 2018 criteria on magnetic resonance imaging (MRI) for the noninvasive diagnosis of hepatocellular carcinoma (HCC) in high-risk patients. Methods: This retrospective study included 273 treatment-naïve patients (71 patients with extracellular contrast agent [ECA]-MRI and 202 patients with hepatobiliary agent [HBA]-MRI; 352 lesions including 263 HCCs) with high risk of HCC who underwent contrast-enhanced MRI between 2016 and 2017. Two readers evaluated all lesions according to the criteria of LI-RADS 2018 and KLCA-NCC 2018. The per-lesion diagnostic performances were compared using the generalized estimating equation method. Results: On ECA-MRI, the sensitivity and specificity of LI-RADS 2018 and KLCA-NCC 2018 were not significantly different (LR-5 vs. definite HCC: 75.8% vs. 69.4%, P=0.095 and 95.8% vs. 95.8%, P>0.999; LR-5/4 vs. definite/probable HCC: 87.1% vs.83.9%, P =0.313 and 87.5% vs. 91.7%, P =0.307). On HBA-MRI, definite HCC of KLCA-NCC 2018 showed significantly higher sensitivity (79.1% vs. 68.2%, P<0.001) than LR-5 of LI-RADS 2018 without a significant difference in specificity (93.9% vs. 95.4%, P=0.314). Definite/probable HCC of KLCA-NCC 2018 had higher specificity (92.3% vs. 80.0%, P=0.003) than LR- 5/4 of LI-RADS 2018. The sensitivity was lower for definite/probable HCC than for LR-5/4 without statistical significance (85.6% vs. 88.1%, P =0.057). Conclusions: On ECA-MRI, LI-RADS 2018 and KLCA-NCC 2018 showed comparable diagnostic performances. On HBA-MRI, definite HCC of KLCA-NCC 2018 provided better sensitivity than LR-5 category of LI-RADS 2018 without compromising the specificity, while definite/probable HCC of KLCA-NCC 2018 revealed higher specificity than LR-5/4 of LI-RADS 2018 for diagnosing HCC.
Abstract
Background/Aims: This study aimed to compare the diagnostic performances of Liver Imaging Reporting and Data System (LI-RADS) 2018 and Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) 2018 criteria on magnetic resonance imaging (MRI) for the noninvasive diagnosis of hepatocellular carcinoma (HCC) in high-risk patients. Methods: This retrospective study included 273 treatment-naïve patients (71 patients with extracellular contrast agent [ECA]-MRI and 202 patients with hepatobiliary agent [HBA]-MRI; 352 lesions including 263 HCCs) with high risk of HCC who underwent contrast-enhanced MRI between 2016 and 2017. Two readers evaluated all lesions according to the criteria of LI-RADS 2018 and KLCA-NCC 2018. The per-lesion diagnostic performances were compared using the generalized estimating equation method. Results: On ECA-MRI, the sensitivity and specificity of LI-RADS 2018 and KLCA-NCC 2018 were not significantly different (LR-5 vs. definite HCC: 75.8% vs. 69.4%, P=0.095 and 95.8% vs. 95.8%, P>0.999; LR-5/4 vs. definite/probable HCC: 87.1% vs.83.9%, P =0.313 and 87.5% vs. 91.7%, P =0.307). On HBA-MRI, definite HCC of KLCA-NCC 2018 showed significantly higher sensitivity (79.1% vs. 68.2%, P<0.001) than LR-5 of LI-RADS 2018 without a significant difference in specificity (93.9% vs. 95.4%, P=0.314). Definite/probable HCC of KLCA-NCC 2018 had higher specificity (92.3% vs. 80.0%, P=0.003) than LR- 5/4 of LI-RADS 2018. The sensitivity was lower for definite/probable HCC than for LR-5/4 without statistical significance (85.6% vs. 88.1%, P =0.057). Conclusions: On ECA-MRI, LI-RADS 2018 and KLCA-NCC 2018 showed comparable diagnostic performances. On HBA-MRI, definite HCC of KLCA-NCC 2018 provided better sensitivity than LR-5 category of LI-RADS 2018 without compromising the specificity, while definite/probable HCC of KLCA-NCC 2018 revealed higher specificity than LR-5/4 of LI-RADS 2018 for diagnosing HCC.
참고문헌 (23)
- Asrani SK, "Burden of liver diseases in the world", J Hepatol, 70, pp.151~171 (2019)
- Marrero JA, "Diagnosis, Staging, and Management of Hepatocellular Carcinoma : 2018 Practice Guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Tang A, "Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ", Abdom Radiol (NY), 43, pp.3~12 (2018)
- Tae-Hyung Kim, "Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update", Clinical and Molecular Hepatology, 25(3), pp.245~263 (2019), 대한간학회
- "CT/MRI LI-RADS® v2018"[URL]
- Park JW, "Practice guideline for diagnosis and treatment of hepatocellular carcinoma", Korean J Hepatol, 10, pp.88~98 (2004)
- Korean Liver Cancer Study Group, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Korean Journal of Radiology, 20(7), pp.1042~1113 (2019), 대한영상의학회[DOI]
- Choi SH, "Diagnostic criteria for hepatocellular carcinoma ≤3 cm with hepatocytespecific contrast-enhanced magnetic resonance imaging", J Hepatol, 64, pp.1099~1107 (2016)
- Joo I, "Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI : can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?", Eur Radiol, 29, pp.1724~1732 (2019)
- Kim DH, "Gadoxetic acidenhanced MRI of hepatocellular carcinoma : value of washout in transitional and hepatobiliary phases", Radiology, 291, pp.651~657 (2019)
- Chernyak V, "Liver Imaging Reporting and Data System(LI-RADS)version 2018 : imaging of hepatocellular carcinoma in at-risk patients", Radiology, 289, pp.816~830 (2018)
- Fowler KJ, "LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma", Abdom Radiol(NY), 43, pp.149~157 (2018)
- Kim YY, "Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System(LI-RADS)in gadoxetate-enhanced MRI", Eur Radiol, 28, pp.2038~2046 (2018)
- Ronot M, "Comparison of the accuracy of AASLD and LI-RADS criteria for the noninvasive diagnosis of HCC smaller than 3 cm", J Hepatol, 68, pp.715~723 (2018)
- Kim DH, "Metaanalysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma", Gut, 68, pp.1719~1721 (2019)
- Brunt E, "cHCC-CCA : consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation", Hepatology, 68, pp.113~126 (2018)
- Fraum TJ, "Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk : diagnostic performance of the Liver Imaging Reporting and Data System version 2014", Radiology, 286, pp.158~172 (2018)
- Jeon SK, "Combined hepatocellular cholangiocarcinoma : LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acidenhanced MR imaging", Eur Radiol, 29, pp.373~382 (2019)
- Min JH, "Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the Liver Imaging Reporting and Data System", Hepatology, 68, pp.2254~2266 (2018)